智通财经APP讯，泰凌医药(01011)公布，该集团预期截至2024年10月31日止十个月将取得公司拥有人应占亏损净额约人民币3500万-3700万元，而2023年同期净亏损约人民币1.529亿元。
公告称，预期亏损净额减少乃主要由于：于本期间并无取得生产及销售中成药业务(该业务由公司前全资附属公司苏州第壹制药有限公司(已于2023年8月由集团出售)经营)亏损(上一期间：亏损约人民币1.1亿元);及该集团于上一期间就两名顾问为集团项目提供有关监督技术及产品注册、调研及开发、制定临床试验的研究计划，以及向监管机构提交临床申请的顾问服务所支付的一次性顾问费用人民币3770万元，而该集团于本期间并无支付任何顾问费用。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.